Small Cell Lung Cancer Extensive Stage Clinical Trial
Official title:
Single-arm, Prospective Clinical Study of PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer
This is a prospective, single-arm clinical study designed to evaluate the 6-month progression-free survival rate (6-month PFS rate) of a PD-L1 inhibitor combined with apatinib as first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The study plans to recruit 40 patients. After receiving 4-6 cycles of induction therapy, patients whose efficacy is evaluated as CR, PR or SD (according to RECIST 1.1) will enter maintenance therapy with PD-L1 inhibitor + apatinib 250 mg po qd. , the selection of PD-L1 inhibitors in the maintenance phase is consistent with the first-line standard treatment in the induction phase. Efficacy was assessed using RECISIT 1.1, with imaging evaluations every 6 weeks (±7 days) for 48 weeks after the first dose and every 9 weeks (±7 days) after week 48, regardless of treatment delays or interruptions, until Disease progression or study termination, whichever occurs first. The primary efficacy endpoint of this study is 6-month PFS rate, and secondary efficacy endpoints include median PFS, median OS and safety.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02179528 -
Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
|
Phase 2 | |
Recruiting |
NCT06030258 -
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
|
Phase 1/Phase 2 | |
Recruiting |
NCT05384015 -
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05745350 -
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
|
Phase 2 | |
Completed |
NCT03325816 -
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05856695 -
A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
Recruiting |
NCT05703971 -
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT00003496 -
Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03059667 -
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03923270 -
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06348797 -
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
|
Phase 1 | |
Active, not recruiting |
NCT04462276 -
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
|
Phase 2 | |
Recruiting |
NCT05680922 -
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04967625 -
A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC
|
Phase 2 | |
Recruiting |
NCT04659785 -
A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer(FA-ES-SCLC)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT05066945 -
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
|
||
Recruiting |
NCT05945745 -
Molecular Analysis and Treatment Options of SCLC
|
||
Not yet recruiting |
NCT03755115 -
SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT05027867 -
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
|
Phase 2 |